» Articles » PMID: 34595169

Suppression of Cell Tumorigenicity by Non-neural Pro-differentiation Factors Via Inhibition of Neural Property in Tumorigenic Cells

Overview
Specialty Cell Biology
Date 2021 Oct 1
PMID 34595169
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Our studies have demonstrated that cell tumorigenicity and pluripotent differentiation potential stem from neural stemness or a neural ground state, which is defined by a regulatory network of higher levels of machineries for basic cell physiological functions, including cell cycle, ribosome biogenesis, protein translation, spliceosome, epigenetic modification factors, reprogramming factors, etc., in addition to the neural stemness specific factors. These machineries and neural stemness factors mostly play cancer-promoting roles. It can be deduced that differentiation requires the repression of neural ground state and causes the reduction or loss of neural ground state and thus tumorigenicity in tumorigenic cells. Formerly, we showed that neuronal differentiation led to reduced tumorigenicity in tumorigenic cells. In the present study, we show that non-neural pro-differentiation factors, such as GATA3, HNF4A, HHEX, and FOXA3 that specify mesodermal or/and endodermal tissues during vertebrate embryogenesis, suppress tumorigenicity via repression of neural stemness and promotion of non-neural property in tumorigenic cells. Mechanistically, these transcription factors repress the transcription of neural enriched genes and meanwhile activate genes that specify non-neural properties via direct binding to the promoters of these genes. We also show that combined expression of HHEX and FOXA3 suppresses tumorigenesis effectively in the AOM/DSS model of colitis-associated cancer. We suggest that targeting the property of neural stemness could be an effective strategy for cancer therapy.

Citing Articles

The uncertainties and certainties of gene transcription in a human tumor cell.

Lv Y, Chen Y, Li X, Li S, Huang Q, Lu R Heliyon. 2024; 10(15):e35529.

PMID: 39166023 PMC: 11334807. DOI: 10.1016/j.heliyon.2024.e35529.


Lack of basic rationale in epithelial-mesenchymal transition and its related concepts.

Cao Y Cell Biosci. 2024; 14(1):104.

PMID: 39164745 PMC: 11334496. DOI: 10.1186/s13578-024-01282-w.


Promoter hypermethylation of neural-related genes is compatible with stemness in solid cancers.

Idris M, Coussement L, Alves M, De Meyer T, Melotte V Epigenetics Chromatin. 2023; 16(1):31.

PMID: 37537688 PMC: 10398991. DOI: 10.1186/s13072-023-00505-7.


Neural induction drives body axis formation during embryogenesis, but a neural induction-like process drives tumorigenesis in postnatal animals.

Cao Y Front Cell Dev Biol. 2023; 11:1092667.

PMID: 37228646 PMC: 10203556. DOI: 10.3389/fcell.2023.1092667.


Proteomic basis of mortality resilience mediated by FOXO3 longevity genotype.

Donlon T, Morris B, Chen R, Lim E, Morgen E, Fortney K Geroscience. 2023; 45(4):2303-2324.

PMID: 36881352 PMC: 10651822. DOI: 10.1007/s11357-023-00740-6.


References
1.
Crompton M, Bartlett T, Macgregor A, Manfioletti G, Buratti E, Giancotti V . Identification of a novel vertebrate homeobox gene expressed in haematopoietic cells. Nucleic Acids Res. 1992; 20(21):5661-7. PMC: 334400. DOI: 10.1093/nar/20.21.5661. View

2.
Xu L, Zhang M, Shi L, Yang X, Chen L, Cao N . Neural stemness contributes to cell tumorigenicity. Cell Biosci. 2021; 11(1):21. PMC: 7814647. DOI: 10.1186/s13578-021-00531-6. View

3.
Kjellev S, Lundsgaard D, Poulsen S, Markholst H . Reconstitution of Scid mice with CD4+CD25- T cells leads to rapid colitis: an improved model for pharmacologic testing. Int Immunopharmacol. 2006; 6(8):1341-54. DOI: 10.1016/j.intimp.2006.04.017. View

4.
Bochkis I, Schug J, Ye D, Kurinna S, Stratton S, Barton M . Genome-wide location analysis reveals distinct transcriptional circuitry by paralogous regulators Foxa1 and Foxa2. PLoS Genet. 2012; 8(6):e1002770. PMC: 3380847. DOI: 10.1371/journal.pgen.1002770. View

5.
Gong W, Su Y, Liu A, Liu J, Sun D, Jiang T . Clinical characteristics and treatments of patients with alpha-fetoprotein producing gastric carcinoma. Neoplasma. 2018; 65(3):326-330. DOI: 10.4149/neo_2018_170207N84. View